UNSPSC 51401537: Mexazolam

This classification denotes a benzodiazepine with the molecular formula C18H16Cl2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S5969B6237, chemically known as 10-chloro-11b-(o-chlorophenyl)-2,3,7,11b-tetrahydro-3-methyloxazolo(3,2-d)(1,4)benzodiazepin-6(5h)-one but generally known as mexazolam, which bears US NIH Compound Identifier 4177. European Medicines Agency schedules Mexazolam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08929MIG.

UNSPSC 51401537 Mexazolam is a Commodity code that captures state and local procurement of benzodiazepine pharmaceuticals, though recent solicitations show the code being applied to broader pharmaceutical supply arrangements. State and local agencies procure under this code through health departments, county health systems, and cooperative purchasing alliances serving multiple jurisdictions. The work spans direct purchase of controlled pharmaceuticals for community health initiatives, multi-state cooperative contracts for generic drugs and over-the-counter products distributed through authorized wholesalers, and exploratory procurement for direct-to-manufacturer pharmacy programs. Issuing bodies include county health departments, state health and human services commissions, and multi-state purchasing organizations; Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) appear as recent active buyers. Vendors must maintain Drug Enforcement Administration licensing, comply with the Drug Supply Chain Security Act and current Good Manufacturing Practices, provide comprehensive insurance coverage including commercial general liability, demonstrate E-Verify compliance, and often work through established pharmaceutical wholesaler networks.

Recent activity centers in Florida and Minnesota with multi-state reach through cooperative agreements. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, response deadline July 26, 2023 (note: date discrepancy in source). MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and weighted evaluation favoring price competitiveness at 75 percent. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. Cooperative purchasing vehicles dominate the landscape, with MMCAP requiring vendors to maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and imposing 3 percent administrative fees and performance penalties.